Sector News

GSK said to be in talks with Qualcomm to form JV: Bloomberg

January 21, 2016
Life sciences

(Reuters) – Pharmaceutical group GlaxoSmithKline Plc (GSK.L) is said to be in discussions with chipmaker Qualcomm Inc (QCOM.O) to form a joint venture as GSK looks for ways to develop medical technology, Bloomberg reported on Wednesday.

The talks are at an initial stage and nothing has been decided, people familiar with matter told Bloomberg. (

GSK declined to comment, while Qualcomm was not immediately available for comments.

Earlier this month, Qualcomm said it was collaborating with Novartis AG (NOVN.VX) (NVS.N) to develop an inhaler for patients suffering from chronic obstructive pulmonary disease.

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach